RT Journal Article
SR Electronic
T1 Losartan, a Selective Inhibitor of Subtype AT1 Receptors for Angiotensin II, Inhibits the Binding of<em>N</em>-Formylmethionyl-leucyl-phenylalanine to Neutrophil Receptors
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 624
OP 628
VO 281
IS 2
A1 Raiden, Silvina
A1 Giordano, Mirta
A1 Andonegui, Graciela
A1 Trevani, Analía S.
A1 López, Daniel H.
A1 Nahmod, Victor
A1 Geffner, Jorge R.
YR 1997
UL http://jpet.aspetjournals.org/content/281/2/624.abstract
AB Losartan, a selective antagonist of AT1 receptors for angiotensin II, is widely used clinically to manage hypertension. We report here that losartan markedly inhibits neutrophil shape change, adherence and chemiluminescence responses triggered byN-formylmethionyl-leucyl-phenylalanine (fMLP), without affecting responses induced by immune complexes, zymosan or concanavalin A. Neither saralasin, another antagonist of angiotensin II receptors, nor captopril, an angiotensin-converting enzyme inhibitor, reproduced the effects of losartan. It was also observed that neutrophil responses triggered by fMLP were not affected by exogenously added angiotensin II. The effect of losartan on the binding of fMLP was measured using [3H]fMLP. It was found that losartan inhibits the binding of [3H]fMLP to neutrophil receptors. As observed for neutrophils, studies performed with monocytes showed that losartan inhibits chemiluminescence emission triggered by fMLP, without affecting chemiluminescence responses triggered by immune complexes, zymosan or concanavalin A. The American Society for Pharmacology and Experimental Therapeutics